FY2026 Earnings Forecast for RAPT Issued By Lifesci Capital

Rapt Therapeutics (NASDAQ:RAPT) – Research analysts at Lifesci Capital increased their FY2026 earnings per share (EPS) estimates for Rapt Therapeutics in a note issued to investors on Sunday, October 12th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings of ($1.58) per share for the year, up from their previous forecast of ($1.59). Lifesci Capital currently has a “Strong-Buy” rating and a $31.00 target price on the stock. The consensus estimate for Rapt Therapeutics’ current full-year earnings is ($2.14) per share.

Several other research firms have also recently weighed in on RAPT. Wall Street Zen raised Rapt Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Barclays set a $35.00 price target on shares of Rapt Therapeutics and gave the company an “overweight” rating in a research report on Monday. Zacks Research downgraded shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 22nd. Leerink Partnrs raised shares of Rapt Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Finally, Leerink Partners upgraded Rapt Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $16.00 to $37.00 in a research note on Friday, September 26th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.78.

Rapt Therapeutics Stock Up 8.1%

Shares of Rapt Therapeutics stock opened at $27.03 on Wednesday. Rapt Therapeutics has a twelve month low of $5.67 and a twelve month high of $32.35. The company has a market cap of $447.08 million, a price-to-earnings ratio of -1.91 and a beta of 0.23. The company’s 50 day moving average is $17.81 and its 200 day moving average is $11.64.

Rapt Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.04).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RAPT. Invesco Ltd. boosted its position in shares of Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after acquiring an additional 47,391 shares during the last quarter. Comerica Bank boosted its holdings in shares of Rapt Therapeutics by 53.9% during the 1st quarter. Comerica Bank now owns 89,327 shares of the company’s stock valued at $109,000 after purchasing an additional 31,287 shares during the last quarter. Callan Family Office LLC boosted its holdings in shares of Rapt Therapeutics by 53.9% during the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company’s stock valued at $109,000 after purchasing an additional 31,287 shares during the last quarter. Checkpoint Capital L.P. purchased a new position in shares of Rapt Therapeutics during the first quarter valued at about $134,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Rapt Therapeutics by 27.7% in the first quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company’s stock worth $139,000 after purchasing an additional 24,662 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.